Publications by B Diaz-Ley

Publications by authors named "B Diaz-Ley"

Actas Dermosifiliogr

October 2023

Hidradenitis suppurativa (HS) is a chronic skin condition characterized by painful lesions and involves high levels of interleukin-23; currently, adalimumab is the only approved treatment, while guselkumab's effectiveness for HS remains unclear.
A multicenter retrospective study included 69 HS patients treated with guselkumab in Spain, focusing on safety and effectiveness through various health scores and patient-reported outcomes over 48 weeks.
Results showed significant improvements in multiple clinical scores, with 58% of patients achieving clinical response by 24 weeks, though some discontinued due to inefficacy; no serious adverse events were reported.

Actas Dermosifiliogr

October 2023

- The study evaluated the effectiveness and safety of guselkumab, a medication targeting IL-23, for treating moderate-severe hidradenitis suppurativa (HS), which is often challenging to manage.
- Conducted in 13 hospitals in Spain, the study involved 69 patients, most of whom had severe HS and had previously tried multiple treatments, including adalimumab. Significant improvements in various clinical scores were noted after 48 weeks of guselkumab treatment.
- About 58% of patients showed a clinical response within 16 weeks, and while some discontinued treatment mainly due to inefficacy, there were no serious side effects reported.